To further study whether c-MYC plays a role in resistance to PRMT5 and MSI2 inhibition, we used the B-cell lymphoma cell line, P-4936 cells, that express c-MYC under the control of a tetracycline-inducible promoter. Here, MYC is linked to B-cell non-Hodgkin lymphoma.